$78.01
1.58%
Nasdaq, Nov 18, 04:00 pm EST. Closed.
ISIN
US10806X1028
Symbol
BBIO

BridgeBio Pharma Inc Stock price

$78.01
+10.07 14.82% 1M
+12.69 19.43% 6M
+1.52 1.99% YTD
+12.42 18.94% 1Y
+48.77 166.79% 3Y
+33.12 73.78% 5Y
+50.46 183.16% 10Y
+50.46 183.16% 20Y
Nasdaq, Closing price Wed, Nov 18 2026
+1.21 1.58%
ISIN
US10806X1028
Symbol
BBIO
Industry

AI Insights on BridgeBio Pharma Inc Insights AI Insights on BridgeBio Pharma Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is BridgeBio Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,090 stocks worldwide.

Key metrics

Basic
Market capitalization
$15.0b
Enterprise Value
$16.8b
Net debt
$1.8b
Cash
$1.5b
Shares outstanding
202.4m
Valuation
P/E
negative
P/S | estimate
15.8 | 13.5
EV/Sales | estimate
17.8 | 15.1
EV/FCF | ex SBC
negative | negative
P/B
negative
Financial Health
Equity Ratio
-222.9%
Return on Equity
34.7%
ROCE
-29.8%
ROIC
-73.7%
Debt/Equity
-2.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$151.8m | 16.1%
SBC as % of FCF
-
SBC Growth 1Y
18.1%
Share Count Growth 1Y
5.1%
Shareholder Yield
-5.1%
Financials
Revenue | estimate
$945.5m | $1.1b
EBITDA
$-348.4m
EBIT
$-353.1m
Net Income
$-592.1m
Free Cash Flow | ex SBC
$-369.8m | $-521.6m
Growth
Revenue | estimate
167.3% | 121.1%
EBITDA
40.9%
EBIT
40.7%
Net Income
25.7%
Free Cash Flow
38.1%
Margin
Gross
94.3%
EBITDA
-36.8%
EBIT
-37.3%
Net
-62.6%
Free Cash Flow | ex SBC
-39.1% | -55.2%
More
EPS
$-3.0
FCF per Share
$-1.8
Short interest
12.0%
Employees
837
Rev per Employee
$600.0k

BridgeBio Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a BridgeBio Pharma Inc forecast:

26x Buy
90%
3x Hold
10%

Analyst Opinions

29 Analysts have issued a BridgeBio Pharma Inc forecast:

Buy
90%
Hold
10%

BridgeBio Pharma Inc Events

Past Events
NOV
16
Jefferies Global Healthcare Conference 2026
3 days ago
OCT
29
Q3 2026 Earnings Call
20 days ago
SEP
23
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
about 2 months ago
SEP
15
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
SEP
10
12th Annual Cantor Fitzgerald Global Healthcare Conference
2 months ago
SEP
9
Wells Fargo 21st Annual Healthcare Conference
2 months ago
AUG
10
Q2 2026 Earnings Call
3 months ago
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
7
Q1 2026 Earnings Call
7 months ago
MAR
11
Barclays 28th Annual Global Healthcare Conference
8 months ago
FEB
24
Q4 2025 Earnings Call
9 months ago
FEB
12
Special Call - BridgeBio Pharma, Inc.
9 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
JAN
9
Special Call - BridgeBio Pharma, Inc.
10 months ago
NOV
10
UBS Global Healthcare Conference 2025
about one year ago
OCT
29
Q3 2025 Earnings Call
about one year ago
OCT
29
Special Call - BridgeBio Pharma, Inc.
about one year ago
OCT
27
Special Call - BridgeBio Pharma, Inc.
about one year ago

Financial data from BridgeBio Pharma Inc

Sep '26
+/-
%
946 946
167% 167%
100%
- Direct Costs 54 54
258% 258%
6%
892 892
163% 163%
94%
- Selling and Administrative Expenses 709 709
52% 52%
75%
- Research and Development Expense 536 536
15% 15%
57%
-348 -348
41% 41%
-37%
- Depreciation and Amortization 4.74 4.74
12% 12%
1%
EBIT (Operating Income) EBIT -353 -353
41% 41%
-37%
Net Profit -592 -592
26% 26%
-63%

In millions USD.

Don't miss a Thing! We will send you all news about BridgeBio Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BridgeBio Pharma Inc Stock News

Neutral
GlobeNewsWire
●
one day ago
PALO ALTO, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced that new Phase 3 ATTRibute-CM analyses and real-world evidence for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) were presented at th...
Neutral
GlobeNewsWire
●
12 days ago
PALO ALTO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on November 5, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 80 new employees in restricted stock units for an aggregate o...
More BridgeBio Pharma Inc News

Company Profile

BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Head office United States
CEO Dr. Kumar
Employees 837
Founded 2015
Website bridgebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today